The Pharmaceutical Society of Japan

Chrono-drug discovery and development based on circadian rhythm of molecular, cellular and organ level

Shigehiro Ohdo, Ph.D.,Professor, Graduate School of Pharmaceutical Sciences, Kyushu University
Biol. Pharm. Bull. vol. 44 No. 6 pp. 747-761

Synthetic Study of polycyclic natural products based on development of new strategy

Atsushi Nishida, Ph.D.,Professor, Institute for Quantitative Biosciences, The University of Tokyo
YAKUGAKU ZASSHI vol. 141 No. 8 pp. 985-994

Development of biological response modifiers based on unique medicinal chemical strategy

Yuichi Hashimoto, Ph.D.,Professor, Institute for Quantitative Biosciences, The University of Tokyo
YAKUGAKU ZASSHI vol. 141 No. 1 pp. 1-13

Functional peptides that target biomembranes: design and modes of action

Shiroh Futaki, Ph.D.,Professor, Institute for Chemical Research, Kyoto University
Chem. Pharm. Bull. vol. 69 No. 7 pp. 601-607

Pharmacological studies on biofunctional molecules in traditional medicines

Hisashi Matsuda, Ph.D.,Professor, Kyoto Pharmaceutical University

Analysis of blood-brain barrier transport mechanism of drugs using the in vitro blood-brain barrier model and the microdialysis technology

Yoshiharu Deguchi, Ph.D.,Professor, aculty of Pharma-Sciences, Teikyo University

Development of intracellular environment-responsive lipid-like material as a multi-DDS technology

Hidetaka Akita, Ph.D.,Professor, Graduate School of Pharmaceutical Sciences, Chiba University
Biol. Pharm. Bull. vol. 43 No. 11 pp. 1617-1625

Exploitation and application of microbial biosynthetic enzymes

Takayoshi Awakawa, Ph.D.,Associate Professor, Graduate School of Pharmaceutical Sciences, The University of Tokyo

Elucidation of physiological functions of membrane proteins as novel drug target candidate molecules

Atsuhiko Ichimura, Ph.D.,Assistant Professor, Graduate School of Pharmaceutical Science, Kyoto University

Synthesis of non-canonical amino acids and peptides containing them for establishment of the template for drug discovery

Tsubasa Inokuma, Ph.D.,Assistant Professor, Graduate School of Biomedical Sciences, Tokushima University
Chem. Pharm. Bull. vol. 69 No. 4 pp. 303-313

Development of site-selective molecular transformation: acylation of hydroxy groups and C-H amination

Yoshihiro Ueda, Ph.D.,Assistant Professor, Institute for Chemical Research, Kyoto University
Chem. Pharm. Bull. vol. 69 No. 10 pp. 931-944

Quantitative proteomics-based elucidation of transport function and pathological molecular mechanism at the blood-brain barrier

Yasuo Uchida, Ph.D.,Lecturer, Graduate School of Pharmaceutical Sciences, Tohoku University
Biol. Pharm. Bull. vol. 44 No. 4 pp. 465-473

Development of a novel strategy for intractable disease therapy with functional nanoparticles

Hiroyuki Koide, Ph.D.,Assistant Professor, Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka
Biol. Pharm. Bull. vol. 44 No. 1 pp. 1-6

Pharmaceutical technology innovation strategy based on the function of blood transport proteins as DDS carriers for the treatment of intractable disorders and cancer

Kazuaki Taguchi, Ph.D.,Senior Assistant Professor, Faculty of Pharmacy, Keio University
Biol. Pharm. Bull. vol. 43 No. 12 pp. 1815-1822

Development of catalytic reactions for precise control of chemoselectivity

Ryo Yazaki,Ph.D.,Assistant Professor, Graduate School of Pharmaceutical Sciences, Kyushu University
Chem. Pharm. Bull. vol. 69 No. 6 pp. 516-525

Yasuhiro Funahashi, Ph.D.,

Deputy Chief Scientific Officer, Oncology Business Group, Eisai Co., Ltd.

Akihiko Tsuruoka, Ph.D.,

Officer, Executive Director, Japan/Asia Clinical Development Department, Medicine Creation, Oncology Business Group, Eisai Co., Ltd.

Junji Matsui, Ph.D.,

Deputy Chief Discovery Officer / Executive Director, Translational Science Department, Medicine Creation, Oncology Business Group, Eisai Inc.

Tomohiro Matsushima, Ph.D.,

Executive Director, Strategy Department, Oncology Business Group, Eisai Co., Ltd.

Kazuki Miyazaki, Master,

General Manager, Department of Innovative Drug Discovery, Research & Development Division, OHARA Pharmaceutical Co., Ltd.

Toshiyuki Kanemasa,

Corporate Planning Department, Corporate Strategy Division,Shionogi & Co., LTD.

Masanao Inagaki, Ph.D.,

Medicinal Chemistry Research Laboratory, Medium Molecular Drug Discovery, Associate Principal Scientist, Shionogi & Co., LTD.,

Tsutomu Suzuki, Ph.D.,

Hoshi University, School of Pharmacy and Pharmaceutical Sciences, Addiction Research Laboratory, Specially Appointed and Emeritus Professor Corporate Strategy Division, Shionogi & Co

Takaaki Yokota , Master,

LTD., Global Development Division, Project Management Department, Shionogi & Co

Minoru Hasegawa, Ph.D.,

LTD., Drug Discovery & Disease Research Laboratory, Vice President, Shionogi & Co.

Koichi Hirai, Ph.D.,

Director, The Research Foundation for Pharmaceutical Sciences

Yasuhiro Tsuji, Ph.D.

Professor, School of Pharmacy, Nihon University
Pharmacometrics for evaluating effect and toxicity based on patients' data and drug model
Biol. Pharm. Bull. vol. 44 No. 9 pp. 1174-1183